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The golden standard in nuclear medicine imaging of inflammation is the use of autologous radiolabeled leukocytes.
Although their diagnostic accuracy is precise, the preparation of the leukocytes is both laborious and potentially
hazardous for laboratory personnel. Molecules involved in leukocyte migration (homing-associated molecules) could
serve as targets for the development of imaging agents for inflammation. An excellent target would be a molecule
that is absent or expressed at low levels in healthy tissues, but is present or upregulated at the sites of
inflammation. In this paper, we will review the literature concerning the use of homing-associated molecules as
imaging targets. We will especially concentrate on vascular adhesion protein-1 due to the promising results
regarding its use as a target for the imaging of inflammation.
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Introduction
Noninvasive imaging of inflammation could be a highly
valuable tool as it could help diagnosing many inflam-
matory conditions, such as osteomyelitis, rheumatoid
arthritis, sarcoidosis, inflammatory bowel disease, and
fever of unknown origin [1,2]. Even though there are
several imaging agents used for the imaging of inflam-
mation by nuclear medicine, none of them are specific
for inflammation [2]. Specific imaging of inflammatory
processes is a demanding task. Unspecific accumulation,
as a result of an increased blood flow and enhanced vas-
cular permeability, increases the signal in the target tis-
sue which makes specific detection difficult. Positron
emission tomography (PET) imaging of inflammation
offers a noninvasive, quantitative approach to diagnosis,
therapy planning, and monitoring and to drug develop-
ment. Nevertheless, clinical applications of this method
are currently limited by the lack of specific imaging
agents to visualize molecular events in vivo. [18F]FDG is
the most widely used PET imaging agent in cancer and
inflammation imaging, but it localizes general inflamma-
tion or cancer and does not define these specifically.* Correspondence: anne.roivainen@utu.fi
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in any medium, provided the original work is pNuclear imaging agents used for inflammation imaging
Nuclear imaging modalities, such as single photon emis-
sion computed tomography (SPECT) and PET, offer func-
tional and molecular information with high sensitivity. Of
these two imaging modalities, PET is more sensitive and
allows for quantitative imaging in a clinical setting [3].
The combination of molecular/functional and anatomic
imaging is preferred in order to identify the exact location
of the functional SPECT/PET signal.
Most of the imaging agents for inflammation imaging
are SPECT imaging agents. Currently, the golden standard
in nuclear medicine imaging of inflammation is autolo-
gous radiolabeled leukocytes [1,2]. They accumulate in the
inflamed tissue by specific leukocyte migration. First, the
injected radiolabeled white blood cells (WBCs) adhere to
the endothelium and further migrate into the tissue. The
leukocytes are labeled either with 99mTc or 111In, with
99mTc being the more commonly used radionuclide due to
its nearly optimal radiation characteristics. However, the
radiolabeling of white blood cells requires a skilled techni-
cian, is laborious, and involves the risk of handling
contaminated blood. Also tissue-specific cells, such as
inflammation-activated osteoblasts in the bone, can be
detected with 99mTc-labeled bisphosphonates. The charac-
teristics of inflammation, such as increased blood flow
and enhanced vascular permeability, can also be exploited
in the imaging of inflammation. These nonspecific eventsOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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and 111In-labeled proteins, such as immunoglobulin G
(IgG) or albumin. In addition to these imaging agents,
67Ga-labeled citrate has also been used in the diagnosis of
inflammatory diseases. [67Ga]citrate binds to transferrin,
and this complex may extravasate to the sites of inflam-
mation due to vascular permeability.
[18F]FDG is used in inflammation imaging with high
sensitivity [4,5]. The uptake of [18F]FDG is dependent on
the metabolic rate of the cell and the number of glucose
transporters. Since activated inflammatory cells show an
increase in the number of glucose transporters, relative to
control conditions, [18F]FDG could be used as a molecular
tracer. In addition, PET, as a technique, allows for the
quantitative measurements of [18F]FDG uptake, making it
possible to evaluate the efficacy of treatment and progres-
sion of the disease. Several inflammatory/infectious condi-
tions, such as fever of unknown origin, focal infections,
osteomyelitis, and vasculitis, can be imaged with [18F]FDG
[4,5]. Although [18F]FDG PET imaging shows potential in
inflammation imaging, the uptake of [18F]FDG is not spe-
cific for inflammatory conditions.
Adhesion molecules as targets for inflammation imaging
Targeting endothelial adhesion molecules may provide
a more specific way to image inflammation through
the detection of endothelial activation. Table 1 shows pos-
sible targets and available imaging agents for this
purpose. Leukocyte migration from the blood into the
non-lymphoid tissues is a hallmark of inflammation. Several
molecules on the leukocyte surface and their counter-
receptors on vascular endothelium mediate a multi-step
adhesion cascade featuring tethering, rolling, activation, ad-
hesion, crawling, and transmigration phases.
Imaging of selectins
Selectins are lectins that reach over the cell membrane and
participate in the rolling step of the adhesion cascade. E-
and P-selectin are expressed on inflamed endothelium inTable 1 Endothelial adhesion molecule candidates for the nu
Target molecule Imaging agent
E-selectin 111In- or 99mTc-labeled anti-E-selectin mAb or
fragments of it
E-selectin 99mTc-labeled E-selectin-binding peptide
P-selectin 99mTc-labeled F(Ab)2 fragment
VCAM-1 123I-labeled VCAM-1 antibody
VCAM-1 123I- and 99mTc-labeled peptides
18F-labeled tetrameric peptide
ICAM-1 111In-labeled ICAM-1 antibody
Integrin αvβ3 18F-, 64Cu-, and 68Ga-labeled RGD peptidesseveral human diseases, such as rheumatoid arthritis (RA)
and inflammatory bowel disease (IBD). Preclinical studies
with radiolabeled anti-E-selectin mAb confirmed the proof-
of-principle of imaging for this endothelial adhesion mol-
ecule. Several animal models, such as the arthritis and gout
model in pigs, proved that specific uptake of 111In-labeled
anti-E-selectin mAb occurs in the inflamed tissue [6,7]. In
addition to gout detection in pigs, Chapman and co-
workers were able to follow the kinetics of E-selectin with a
labeled antibody [7]. This 111In-labeled intact (murine)
mAb was able to detect E-selectin on activated endothe-
lium in vivo in patients with RA [8]. In comparison to
human immunoglobulin G, an established imaging agent
for RA, anti-E-selectin mAbs provided images with super-
ior quality. In addition, labeled anti-E-selectin mAb showed
good immunogenicity, since no human anti-mouse anti-
bodies were detected at 12 to 14 days after mAb injection.
Also, IBD in the patient was detected with 111In-labeled E-
selectin Ab, and these results were comparable to radiola-
beled WBCs [9]. Even though intact mAbs showed promise
in E-selectin targeting and RA imaging, they are large mole-
cules and suffer from slow blood clearance. To address this
issue, a smaller fragment of the antibody was labeled with
99mTc and used in the imaging of joint inflammation in
patients [10]. 99mTc-labeled Fab fragment of the mAb
showed specific uptake as early as 4 h after the injection, in
comparison to a nonspecific antibody. In addition to the
antibody approach, a peptide labeled with 99mTc shows
promise in the imaging of inflamed synovium in a rat
model of arthritis [11].
Imaging of immunoglobulin superfamily members
The immunoglobulin superfamily is a family of cell sur-
face receptors, which participate in many tasks, includ-
ing antigen recognition and binding of the complement.
Five of the members in this family participate in leukocyte
adhesion, interacting mainly with integrins. Vascular cell
adhesion molecule-1 (VCAM-1) and intercellular adhe-
sion molecule 1 (ICAM-1) mediate arrest in the leukocyteclear imaging and currently available imaging agents
Imaged condition Reference
Arthritis of pig, a pig model of gout, patients
with RA, patients with IBD
[6-10]
Rat model of arthritis [11]
Pulmonary embolism in beagle dog [12]
Colitis in rat [13]
Atherosclerosis in rabbit, atherosclerotic
plaques in mice
[14,15]
Lung injury in rat [16]
Mouse model of chronic inflammation, acute
and chronic model of inflammation in mice,
atherosclerotic plaques in mice
[17-20]
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many inflammatory conditions. To date, only preclinical
studies exist regarding imaging agents targeting VCAM-1
and ICAM-1. 111In-labeled antibody against ICAM-1 is
specifically able to detect bleomycin-induced lung injury
in rats as early as 4 h after induction [16]. Several animal
models, such as the experimental model of colitis in rats,
atherosclerosis in the rabbit model and atherosclerotic
plaques, in mice, have been evaluated with VCAM-1 tar-
geting imaging agents [13-15].
Imaging of integrins
Integrins are a large member of adhesion molecules. The
most extensively studied member of the integrin family
is the integrin αvβ3. Integrin αvβ3 is a molecule which
mediates the migration of endothelial cells through the
basement membrane during blood vessel formation. This
integrin is significantly upregulated on activated endothe-
lial cells during angiogenesis, but not on inactive endothe-
lial cells. This integrin serves as a molecular marker for
tumor angiogenesis and metastasis imaging. In addition to
cancer angiogenesis, integrin αvβ3 expression is also found
during wound healing, RA, psoriatic plaques, and during
restenosis. Noninvasive monitoring of the molecular pro-
cesses during angiogenesis would supply helpful informa-
tion for clinicians, as well as for basic scientists. The most
successful imaging agents for PET and SPECT imaging of
integrin αvβ3 are described [21-23].
Although, all clinical imaging studies with arginine-
glycine-aspartic acid (RGD)-peptides concern cancer
patients, imaging of αvβ3 integrin may become a new
biomarker for disease activity in inflammatory processes.
Integrin αvβ3 expression exists in many inflammatory
diseases, such as RA. In imaging studies, only preclinical
studies have exploited this opportunity. The radiolabeled
RGD peptide accumulates in chronically inflamed tissue
in mice due to of αvβ3-specific binding, and this process
can be monitored noninvasively with PET [17]. Also, the
chronic phase of inflammation showed a higher uptake
in comparison to acute inflammation evaluated by the
64Cu-labeled tetrameric RGD peptide [18]. In addition to
these chemically induced inflammatory models, radiola-
beled RGD peptides show specific accumulation in ath-
erosclerotic plaques in genetically modified mice, which
spontaneously develop atherosclerotic lesions [19,20].
Vascular adhesion protein-1
Vascular adhesion protein-1 (VAP-1/SSAO) is an endo-
thelial cell adhesion molecule that is rapidly translocated
from the intracellular storage granules to the endothelial
cell surface upon inflammation. VAP-1 participates in
the recruitment of leukocytes to the sites of inflamma-
tion. It plays a role during the rolling, adhesion, and trans-
migration steps in the extravasation cascade mediating thejourney of a leukocyte from the blood into the tissue [24].
The early translocation of VAP-1 makes it an optimal can-
didate for anti-inflammatory therapy and a potential target
for the in vivo imaging of inflammation.
VAP-1 is a membrane-bound homodimer with the mo-
lecular weight of approximately 90 kDa per monomer [25].
Unlike the conventional homing-associated endothelial
molecules, VAP-1 is also an enzyme. It degrades primary
amines and produces hydrogen peroxide, ammonium and
aldehyde as its enzymatic end products - all potent inflam-
matory mediates. Dietary methylamine is one of its sub-
strate, but it can also use one of its leukocyte ligands,
Siglec-10 as a substrate [26]. The crystal structure of VAP-
1 is known [27]. The molecule has a heart-shaped fold
that contains a transmembrane domain and extracellular
domains. The D4 domain includes the enzymatically ac-
tive site buried deep in the globular head of the molecule.
The heart of the active site is the topaquinone that is the
co-factor necessary for enzymatic activity. The active site
is large enough to accommodate an amino acid side
chain and might interact with a larger molecule, such as
a peptide or protein ligand. VAP-1 contains several sites
for glycosylation. Glycosylation is necessary for VAP-1
to function properly during leukocyte adhesion.
The current working hypothesis for leukocyte binding
to VAP-1 describes this binding as having a dual mode
of function, as described by Salmi and Jalkanen [28].
The leukocyte first makes contact with VAP-1 expressed
on the endothelial cells by using its counter receptor to
interact with the surface of VAP-1. This part is played by
the VAP-1 epitope(s) recognized by certain monoclonal
antibodies. After this initial contact, an amine in the sur-
face of the leukocyte binds into the substrate channel of
VAP-1. This leads to an enzymatic reaction between the
leukocyte ligand (substrate) and the endothelial VAP-1.
These two events are connected because the enzymatic
function is needed for leukocyte binding [29]. Blocking
of the antibody binding site with anti-VAP-1 monoclonal
antibodies, as well as the inhibition of the enzymatic ac-
tivity, reduces the number of adherent cells under flow
conditions [30].
Even though VAP-1 plays an important role in the
early events of inflammation, the expression of VAP-1
on the cell surfaces stays constant for a longer time peri-
ods, if the inflammation continues. This suggests that
VAP-1 can still be targeted after the first phase of in-
flammation and makes it a promising target for anti-
adhesive therapy [31]. Several animal models exist to
obtain knowledge of the role of VAP-1 in human patholo-
gies. For example, VAP-1 mediates lymphocyte binding to
the vascular endothelium in rejected kidney allografts as
well as in the liver allograft in rats [32,33]. VAP-1 also
plays a role in neurological diseases such as forebrain is-
chemia and experimental autoimmune encephalitis, which
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knockout and transgenic mice have confirmed the role of
VAP-1 as an inflammatory adhesion molecule - know-
ledge that was originally obtained from inhibitory studies
with antibodies [30,36].
VAP-1 as a target for imaging
Imaging agents targeting VAP-1 could be valuable not
only for the diagnosis and planning of treatment for
patients, but also for the drug discovery and develop-
ment processes. In addition to therapy monitoring, VAP-
1 imaging would provide a scientific tool for in vivo
imaging of leukocyte trafficking at the sites of inflamma-
tion. Several publications have appeared, to date, con-
cerning VAP-1 in imaging (Table 2).
The first publication to show the potential of VAP-1 as
a target for in vivo imaging was conducted by Jaakkola
and co-workers [31]. Anti-human-VAP-1 mAb 1B2 was
labeled with 123I using the chloramine T method and eval-
uated in animal models of skin inflammation and aseptic
arthritis. Inflammation was visualized and the uptake was
specific in comparison to a simultaneously injected non-
specific antibody.
Exploiting the knowledge of the crystal structure of
VAP-1, several small peptides were modeled to fit to the
enzymatic groove of VAP-1. A specific lysine-containing
peptide was found to be the inhibitor of the enzymatic
activity of VAP-1 [42]. The peptide, GGGGKGGGG, was
tested in functional binding assays and it effectively
inhibited lymphocyte-endothelial-cell interaction under
conditions of flow. This peptide was labeled with 68Ga
and further evaluated as an imaging agent for PET im-
aging [37,39]. The preclinical testing of the VAP-1 pep-
tide, 68Ga-DOTAVAP-P1, was positive when assessing
in vivo stability, tissue distribution, and biokinetics. In
vivo specificity exists in an animal model of osteomye-
litis in comparison to negative control peptides, modeled
to fit poorly in the enzymatic loop of VAP-1, and to two
competitors (semicarbazide and an unlabeled peptide
(DOTAVAP-P1). The study revealed a significantly lower
uptake in the infected site for all negative controls. In
comparison to [18F]FDG, 68Ga-DOTAVAP-P1 showed aTable 2 Nuclear medicine imaging studies with VAP-1 targeti
Imaging agent Imaged condition
123I-labeled anti-human-VAP-1 mAb 1B2 Animal models of skin inflamma
68Ga-labeled VAP-1 binding peptide, 68Ga-
DOTAVAP-P1
Animal model of osteomyelitis
68Ga-labeled VAP-1 binding peptide, 68Ga-
DOTAVAP-P1
Animal model of sterile skin infl
68Ga-labeled VAP-1 binding peptide, 68Ga-
DOTAVAP-PEG-P1
Animal model of sterile skin infl
68Ga-labeled VAP-1 binding peptide, 68Ga-
DOTA-Siglec-9 peptide
Animal model of sterile skin infl
transgenic mouse and VAP-1 knslightly lower target-to-background ratio in a rat model
of osteomyelitis. 68Ga-DOTAVAP-P1 was also able to ac-
curately demonstrate the phase of inflammation in heal-
ing bones and the progress of a Staphylococcus aureus
bacterial infection in osteomyelitic bones [37]. The up-
take of 68Ga-DOTAVAP-P1 at the site of inflammation in
an experimental sterile skin inflammation model was
comparable to [18F]FDG. The results of 68Ga-DOTAVAP-
P1 were in line with the expression of luminal VAP-1,
which was high at the site of inflammation [39]. In all of
these studies, intravenously administered 68Ga-DOTA
VAP-P1 exhibited rapid excretion through the kidneys to
the urinary bladder. Notable retention in the liver and very
low radioactivity in the brain was observed. The high
hydrophilicity of 68Ga-DOTAVAP-P1 (logD, −4.5) gives an
explanation for the rapid renal excretion [38].
In the next study, 68Ga-DOTAVAP-P1 was chemically
modified by adding a PEG linker to improve its pharma-
cokinetic properties [40]. The incorporation of a mini-
PEG spacer in 68Ga-DOTAVAP-P1 enhanced its in vivo
stability and improved PET imaging of the inflammation.
This modification had no apparent effect on the in vitro
properties of the VAP-1 binding peptide. Both peptides
were stable in plasma incubations in vitro and their solu-
bility was very similar. However, when intravenously
administered, 68Ga-DOTAVAP-PEG-P1 showed signifi-
cantly longer metabolic and elimination half-lives and
slower total clearance compared to 68Ga-DOTAVAP-P1.
Furthermore, our results revealed that while both pep-
tides were able to detect experimental inflammation by
PET imaging, 68Ga-DOTAVAP-PEG-P1 showed a higher
inflammation-to-muscle ratio than the original 68Ga-
DOTAVAP-P1. The renal excretion of 68Ga-DOTAVAP-
PEG-P1 was slower, resulting in significantly lower
urinary bladder radioactivity in comparison to 68Ga-
DOTAVAP-P1.
Recently, a phage-display method discovered a novel
VAP-1 binding peptide [41]. When further studies were
conducted, this peptide was revealed to belong to an un-
known leukocyte ligand of VAP-1. This peptide was part
of a Siglec-9 molecule that is found on granulocytes and
macrophages. The combination of VAP-1 as a target andng agents
Reference
tion and aseptic arthritis [31]
[37,38]
ammation and pancreatic adenocarcinoma xenograft in rat [39]
ammation in rat [40]
ammation in rat, DNBC-induced skin inflammation in hVAP-1
ockout mouse
[41]
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a theoretically optimal setting. This peptide was labeled
with 68Ga and used in PET imaging studies of experi-
mental inflammation. Transgenic mice expressing human
VAP-1 on endothelium showed a higher signal in chem-
ically induced ear inflammation, in comparison to the
control site, and to VAP-1 deficient knockout mice. The
labeled peptide showed preferred renal excretion and
some uptake in the liver.
All of these peptides were tested using the same
turpentine-induced rat model of sterile inflammation,
and the results can thus be compared. All of these pep-
tides were able to detect inflammation from the back-
ground muscle in this model, as seen in Figure 1. Peptides
had high target-to-non target ratios (above 6) and showed
rapid uptake in the inflammatory foci as well as preferred
renal clearance and some uptake in the liver. The standar-
dized uptake values derived from PET images were 0.33 ±
0.07, 0.53 ± 0.01, and 0.45 ± 0.06 for 68Ga-DOTAVAP-P1,
68Ga-DOTAVAP-PEG-P1, and 68Ga-DOTA-Siglec-9 pep-
tide, respectively, at 60 min after injection.
Due to its novel characteristics among various homing-
associated molecules, VAP-1 has certain benefits as a tar-
get for imaging inflammation. Unlike ICAM-1, VCAM-1,
and integrin αvβ3, it is hardly detected on the endothelium
in normal conditions, thus theoretically providing better
specificity to detect inflammation. Moreover, its enzymatic
activity provides additional ways to design imaging targets
in comparison to endothelial selectins.
Limitations in VAP-1 imaging
VAP-1 binding peptides and antibodies have few limita-
tions in PET imaging. The imaging of the abdomen areaFigure 1 VAP-1 targeting imaging agents in detecting inflammation.
of sterile skin/muscle inflammation. All the images fall within the same rad
(b) Inflammation-to-muscle ratios obtained from PET imaging at 60 min aftis limited, since the liver shows high uptake. The liver
uptake is, at least in part, due to the high number of VAP-
1 receptors in the sinusoidal endothelial cells in the
human liver [43]. Some degradation products of 68Ga-
DOTA-peptides, such as free 68Ga, also tend to accumu-
late in the liver [44]. In studies with 68Ga-labeled Siglec-9
peptide and blocking and a comparison of VAP-1 positive
WT mice and VAP-1 negative KO mice revealed 60% and
50% specific binding of the peptide in the livers of each
genotype of mouse, respectively [41]. Since VAP-1 has a
soluble form in the circulation, which is enzymatically
cleaved from the endothelial cell surface [30], the binding
of labeled peptides to soluble VAP-1 might theoretically
limit their use as an imaging target in cases in which the
soluble VAP-1 concentrations are very high. In our pre-
clinical studies, all inflammatory and cancer focuses were
detectable from the background tissue, indicating that the
soluble form does not present an issue. In addition, the
excretion to the urine via the kidneys limits the use of
these peptides for imaging of the pelvic area.
A tracer capable of distinguishing between microbial
infection and sterile inflammation would have clinical
value. Unfortunately, VAP-1 targeting agents are not prob-
ably able to do this, since VAP-1 is expressed, at least in
some bacterial infections, as well as in the sterile inflam-
mation [37]. However, the inclusion of kinetic PET data
will likely give rise to a better quantification of VAP-1 ex-
pression in local tissues.
Future prospects
VAP-1 is upregulated in many human inflammatory dis-
eases, such as acute myocardial infarction, inflammatory
bowel disease and rheumatoid arthritis [45-48]; and a(a) PET images of 68Ga-labeled VAP-1 binding peptides in a rat model
ioactivity scale and the scale bar is shown on the left.
er injection.
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trials for patients suffering from rheumatoid arthritis
and psoriasis [49]. Leukocyte extravasation from the
blood into inflamed tissues plays a crucial role in the
pathogenesis of these diseases and therefore, molecular
imaging of the adhesion molecules expressed on the vas-
culature of the target organs, in these diseases, could
help in the diagnosis and evaluation of the severity of
these diseases. Moreover, successful imaging could be
beneficial in the selection of patients for specific anti-
body treatment and in monitoring of these treatments
and disease progression. This approach could also be
utilized in VAP-1 specific drug development and the se-
lection of patients for clinical trials.
Conclusions
During recent years, several publications reporting the use
of homing-associated endothelial cell molecules as targets
to image inflammation emerged. As being important in
leukocyte trafficking to the sites of inflammation, they are
logical targets for developing novel agents for imaging.
Over time, a molecular targeting strategy is likely to prevail
over the existing white cell labeling technique. One of the
most promising candidates among the homing-associated
molecules is VAP-1 due to its unique characteristics in
being both an adhesion and enzymatic molecule. Moreover,
its rapid translocation to the endothelial cell surface at the
sites of inflammation increases its potential as an imaging
target. Several preclinical studies of VAP-1 targeting with
PET imaging agents exist, and successful detection of
VAP-1 in the vasculature is described. These results
strongly suggest that VAP-1 could be used as a target in
the diagnosis of various inflammatory conditions also in
humans. Future studies will show how well these expecta-
tions are fulfilled.
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